Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ By Sam | February 14, 2018 The deal includes a licence to use OXB’s LentiVector Enabled technology and access to its industrial-scale manufacturing technology. Source: BioSpace Posted in BioPharma